Abstract
BackgroundTofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA). Small increases in mean serum creatinine...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have